Bio-Path (NASDAQ:BPTH) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report issued on Saturday morning. The brokerage issued a sell rating on the stock.

Bio-Path Price Performance

Shares of NASDAQ:BPTH opened at $0.19 on Friday. The company’s fifty day moving average price is $0.85 and its 200-day moving average price is $0.94. Bio-Path has a one year low of $0.12 and a one year high of $9.80.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.